Comprehensive Library Of Resveratrol News

If it is a patentable synthetic molecule that could make research institutions and pharmaceutical companies billions of dollars, it will surely be heralded.  But if it is an un-patentable natural molecule that does the same thing at far less cost, it will predictably be dismissed.

That is the current state of affairs when it comes to technology that would limit damage caused by a heart attack.

Researchers at Yale University report their MIF20 small molecule reduced damage to heart muscle by ~40% in an experimental animal model.   The Yale researchers report their findings here.

These Yale researchers “Suggest that augmentation of endogenous MIF signal transduction via pharmacological activation” to address “susceptibility to ischemic (heart) tissue damage.”

But what happened to resveratrol, the once heralded red wine molecule that does the same thing?

Dr. Dipak Das is credited with conducting the most voluminous data showing resveratrol limits damage to heart muscle tissue after a heart attack, even to the point of showing a particular brand of resveratrol produced even greater protection than plain resveratrol.  His work was even validated by researchers at the National Institutes of Health using microRNA analysis.

But many of his published papers were later retracted under false allegations of scientific fraud, even though his work as corroborated by independent researchers.  Some of that research pre-dates the work of Dr. Das, having been demonstrated over a decade ago, but goes unused by cardiologists.

An economical and widely available resveratrol dietary supplement that could be like aspirin to limit damage from a heart attack could be utilized by millions of adults.  A synthetic drug would likely be limited to post-heart attack patients to prevent second heart attacks and is likely to be costly.  As an aside, aspirin has fallen from grace and is only modestly prevents non-mortal heart attacks.  ©2013 Bill Sardi, ResveratrolNews.com